Zacks Research Lifts Earnings Estimates for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Zacks Research boosted their Q2 2028 earnings per share (EPS) estimates for shares of Globus Medical in a note issued to investors on Monday, June 22nd. Zacks Research analyst Team now anticipates that the medical device company will post earnings per share of $1.28 for the quarter, up from their prior estimate of $1.27. The consensus estimate for Globus Medical’s current full-year earnings is $4.74 per share.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm’s revenue was up 27.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS.

GMED has been the subject of several other research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Wall Street Zen cut shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Needham & Company LLC upped their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Royal Bank Of Canada upped their price objective on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Finally, Piper Sandler decreased their target price on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $105.00.

Globus Medical Stock Down 3.8%

Shares of NYSE:GMED opened at $75.99 on Thursday. Globus Medical has a twelve month low of $51.79 and a twelve month high of $101.40. The firm has a market capitalization of $10.32 billion, a price-to-earnings ratio of 17.67, a PEG ratio of 1.63 and a beta of 0.95. The stock’s 50 day moving average is $82.66 and its 200-day moving average is $87.22.

Insider Transactions at Globus Medical

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares in the company, valued at $41,201,733. The trade was a 4.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 18.38% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Several institutional investors have recently made changes to their positions in the business. Pacer Advisors Inc. boosted its holdings in shares of Globus Medical by 3.6% in the first quarter. Pacer Advisors Inc. now owns 34,365 shares of the medical device company’s stock worth $2,961,000 after buying an additional 1,188 shares during the last quarter. Defilade Capital Management L.P. increased its holdings in Globus Medical by 32.6% during the first quarter. Defilade Capital Management L.P. now owns 354,350 shares of the medical device company’s stock valued at $30,531,000 after buying an additional 87,138 shares during the last quarter. NewEdge Advisors LLC increased its holdings in Globus Medical by 20.0% during the first quarter. NewEdge Advisors LLC now owns 30,540 shares of the medical device company’s stock valued at $2,631,000 after buying an additional 5,091 shares during the last quarter. Glenmede Trust Co. NA boosted its stake in shares of Globus Medical by 22.8% during the 1st quarter. Glenmede Trust Co. NA now owns 225,446 shares of the medical device company’s stock worth $19,424,000 after acquiring an additional 41,801 shares during the last quarter. Finally, Summitry LLC boosted its stake in shares of Globus Medical by 2.6% during the 1st quarter. Summitry LLC now owns 8,205 shares of the medical device company’s stock worth $707,000 after acquiring an additional 211 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.